Compare NeoGenomics Inc. Common Stock (NEO) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NeoGenomics Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 4.9× NeoGenomics Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is more actively traded (2,644,694 versus 2,228,400). Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| NEO | PCVX | |
|---|---|---|
Market Cap | $2.14B | $10.51B |
Volume | 2,228,400 | 2,644,694 |
Sector | Health | Health |
52-Week High | $19.91 | $73.82 |
52-Week Low | $7.19 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.44B | $9.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
